口服抗癌药物依从性与老年转移性肾细胞癌患者生存
基于SEER-Medicare的回顾性队列研究纳入2007至2015年间接受口服抗癌药物治疗的905例转移性肾细胞癌患者,49.2%在起始治疗后3个月内依从(PDC>80%)。居住于贫困社区(OR 0.49,CI 0.33-0.74)和自付费用>200美元(OR 0.68,CI 0.47-0.98)与依从性降低相关;依从性与2年生存改善相关(单因素logrank P=.01),多因素分析中全因死亡(HR 0.87,CI 0.72-1.05)和肾癌特异性死亡(HR 0.84,CI 0.69-1.03)呈非显著趋势。
要点
- 49.2%的老年转移性肾细胞癌患者在起始口服抗癌药后3个月内依从(PDC>80%)。
- 居住于贫困社区(OR 0.49)和自付费用>200美元(OR 0.68)与依从性降低相关。
- 依从性与2年生存改善相关(单因素P=.01),多因素分析全因死亡HR 0.87(CI 0.72-1.05)、肾癌特异性死亡HR 0.84(CI 0.69-1.03)呈非显著趋势。
核心结论
- 局部贫困水平和高自付费用与Medicare转移性肾细胞癌患者口服抗癌药物初始依从性差相关,进而提示总生存和疾病特异性生存呈不良趋势。
研究设计与样本
- SEER-Medicare回顾性队列研究,纳入2007至2015年间接受口服抗癌药物治疗的转移性肾细胞癌患者,共905例符合标准。
主要发现
- 445例(49.2%)被归类为对初始口服抗癌药物治疗依从。
- 居住于贫困社区与依从性降低相关(OR 0.49,CI 0.33-0.74)。
- 自付费用>200美元与依从性降低相关(OR 0.68,CI 0.47-0.98)。
- 依从性与2年生存改善相关(单因素logrank检验,P=.01)。
- 多因素分析中,依从性与全因死亡(HR 0.87,CI 0.72-1.05)和肾癌特异性死亡(HR 0.84,CI 0.69-1.03)呈非显著趋势。
临床怎么用
- 作者认为,改善更广泛转移性肾细胞癌人群结局的努力应纳入口服抗癌药物依从性和经济因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine real-world adherence to oral anticancer agents (OAAs) and its association with outcomes among Medicare beneficiaries with metastatic renal cell carcinoma (mRCC). METHODS: SEER-Medicare retrospective cohort study of patients with metastatic renal cell carcinoma (mRCC) who received an OAA between 2007 and 2015. We examined A) adherence and B) overall and disease-specific 2-year survival landmarked at 3 months after OAA initiation. Adherence was assessed by calculating the proportion of days covered (PDC) within 3 months of OAA initiation, with adherent use being defined as PDC > 80%. RESULTS: A total of 905 patients met study criteria, of whom 445 patients (49.2%) were categorized as adherent to initial OAA treatment. Adjusting for clinical and demographic factors revealed decreased odds of adherence associated with living within an impoverished neighborhood (OR 0.49, CI 0.0.33 - 0.74) and out-of-pocket costs > $200 (OR 0.68, CI 0.47-.98). Adherence was associated with improved 2-year survival in univariate analysis (logrank test, P = .01) and a non-significant trend toward an association with decreased all-cause (HR 0.87, CI 0.72 - 1.05) and RCC-specific survival (HR 0.84, CI 0.69 - 1.03) in multivariable analysis. CONCLUSION: Local poverty levels and high out-of-pocket costs are associated with poor initial adherence to OAA therapy in Medicare beneficiaries with mRCC, which in turn, suggests a trend toward poor overall and disease-specific survival. Efforts to improve outcomes in the broader mRCC population should incorporate OAA adherence and economic factors.
引用
- Dinan MA, Wilson LE, Greiner MA, et al. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC). Urology. 2022. PMID: 35878815. doi:10.1016/j.urology.2022.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。